AbCellera Biologics WKN: A2QKXS ISIN: CA00288U1066 Kürzel: ABCL Forum: Aktien Thema: Hauptdiskussion

Sarkasmus! Is bei mir halt Scheisse gelaufen! Muss halt mal sein!!

Bei 5 kauf ich nach! Dann hab ich meinen EK auch etwas verbessert:-)))))

Heyyyyy, eine 3 vor dem Komma! Nur noch 13 bis zur 16. Gleich hammers!

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced that it has entered into a settlement and patent license agreement with Bruker Corporation, resolving the patent litigation between the two companies globally. As part of the settlement, Bruker will pay AbCellera $36 million up front as well as future royalty payments on sales of Bruker's Beacon® Optofluidic platform products worldwide through the life of the licensed patents.

AbCellera and Bruker Reach Global Settlement of Patent Litigation

16 usd was für ein traum 🤣🥲

Kursziel 16,00 USD https://de.marketscreener.com/kurs/aktie/ABCELLERA-BIOLOGICS-INC-116373768/analystenerwartungen/

Wegen??

Jetzt schaffen wir die 1 vorne auch noch!

🥴

Das Form 4 muss eingereicht werden, wenn Insider (z. B. Großaktionäre, Führungskräfte oder relevante Beteiligte) ihre Beteiligungen an einem börsennotierten Unternehmen ändern.  • Hier meldet Thermopylae Holdings Ltd., als “Reporting Person”, eine Änderung bei den Aktien­beständen von AbCellera.  • Am 03.11.2025 hat Thermopylae Holdings 343.631 „Common Shares“ von AbCellera erworben (Transaktions-Code “P V” für Purchase via Plan), zum durchschnittlichen Preis von 2,16 USD pro Aktie.  • Nach der Transaktion hält Thermopylae insgesamt 56.143.640 Aktien von AbCellera.

Insider Aktienkauf

???

https://www.sec.gov/Archives/edgar/data/1703057/000162828025012154/xslF345X05/wk-form4_1741732971.xml

Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution? Abdul Rahman Tue, November 18, 2025 at 12:17 PM GMT+1 2 min read AbCellera Biologics Inc. (NASDAQ:ABCL) is a must-buy penny stock to buy now. On November 13, at the Stifel 2025 Healthcare Conference, AbCellera Biologics Inc. (NASDAQ:ABCL) reaffirmed its strategic evolution into a company focused on developing clinical assets. The company will no longer operate under a partnership model but will develop its own assets backed by a strong financial position. With over $500 million in cash and equivalents, AbCellera is focused on the development of ABCL635, a first-in-class antibody medicine for the non-hormonal treatment of moderate to severe menopausal hot flashes. The company is also working on ABCL575, an antibody for the treatment of moderate-to-severe atopic dermatitis (AD). Even as the company continues to work on its clinical assets, strategic partnerships with big Pharma, including Eli Lilly and AbbVie, are crucial. The internal clinical assets are only seen as a presale activity for future licensing. Amid the new strategic focus, on November 7, TD Cowen analyst Brendan Smith reiterated a Buy rating, as Stifel Nicolaus analyst Stephen Wiley echoed similar sentiments with a Buy rating and a $7 price target. https://finance.yahoo.com/news/why-wall-street-maintains-buy-111713708.html

Ich kann es nicht öffnen: https://www.tipranks.com/news/ratings/strategic-shift-and-promising-antibody-therapeutics-drive-buy-rating-for-abcellera-biologics-ratings?mod=mw_quote_news